Your browser is no longer supported. Please, upgrade your browser.
RETA Reata Pharmaceuticals, Inc. daily Stock Chart
RETA [NASD]
Reata Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-10.73 Insider Own0.10% Shs Outstand33.27M Perf Week-14.70%
Market Cap3.49B Forward P/E- EPS next Y-10.51 Insider Trans2.79% Shs Float27.10M Perf Month-10.62%
Income-343.20M PEG- EPS next Q-1.98 Inst Own82.20% Short Float13.04% Perf Quarter-39.25%
Sales15.30M P/S227.97 EPS this Y-228.10% Inst Trans2.02% Short Ratio10.15 Perf Half Y-34.34%
Book/sh6.96 P/B13.62 EPS next Y-34.10% ROA-60.80% Target Price- Perf Year18.05%
Cash/sh16.59 P/C5.71 EPS next 5Y- ROE-211.30% 52W Range73.38 - 257.96 Perf YTD-53.64%
Dividend- P/FCF- EPS past 5Y- ROI-45.40% 52W High-62.57% Beta1.58
Dividend %- Quick Ratio13.60 Sales past 5Y-12.60% Gross Margin- 52W Low31.57% ATR5.48
Employees220 Current Ratio13.60 Sales Q/Q-60.30% Oper. Margin- RSI (14)36.64 Volatility7.71% 5.34%
OptionableYes Debt/Eq0.30 EPS Q/Q-77.70% Profit Margin- Rel Volume0.64 Prev Close94.78
ShortableYes LT Debt/Eq0.30 EarningsAug 10 BMO Payout- Avg Volume347.97K Price96.55
Recom1.10 SMA20-4.98% SMA50-17.72% SMA200-39.62% Volume183,858 Change1.87%
Jul-10-20Resumed Stifel Buy $315 → $280
Jun-17-20Initiated BTIG Research Buy $237
Nov-13-19Downgrade National Securities Buy → Neutral
Sep-26-19Initiated National Securities Buy $130
Sep-25-18Reiterated Leerink Partners Outperform $116 → $139
Sep-13-17Initiated Leerink Partners Outperform $43
Jul-25-17Reiterated Citigroup Buy $39 → $87
Apr-13-17Initiated Ladenburg Thalmann Buy $55
Feb-23-17Initiated Stifel Buy $38
Jan-25-17Initiated Robert W. Baird Outperform $43
Jun-20-16Initiated Piper Jaffray Overweight $33
Jun-20-16Initiated Citigroup Buy
Sep-16-20 11:26AM  
Sep-14-20 09:50AM  
Sep-09-20 11:30AM  
Sep-03-20 06:45AM  
Aug-14-20 09:22AM  
Aug-12-20 11:10PM  
Aug-11-20 11:41AM  
11:26AM  
Aug-10-20 07:31PM  
02:12PM  
08:05AM  
07:15AM  
06:45AM  
Aug-03-20 06:45AM  
Jul-30-20 04:05PM  
Jul-28-20 06:45AM  
Jul-13-20 05:02PM  
Jul-07-20 06:45AM  
Jul-03-20 04:53PM  
Jun-30-20 02:40PM  
Jun-24-20 10:10AM  
Jun-19-20 08:43AM  
Jun-18-20 09:42AM  
Jun-12-20 06:31PM  
11:02AM  
Jun-11-20 07:30AM  
Jun-10-20 11:30AM  
Jun-03-20 12:55PM  
May-12-20 03:00PM  
10:45AM  
May-11-20 06:45PM  
04:01PM  
May-04-20 04:35PM  
Apr-13-20 01:06PM  
Apr-07-20 09:50AM  
Mar-31-20 04:28PM  
08:26AM  
Mar-30-20 04:05PM  
Mar-22-20 08:30PM  
Mar-20-20 11:30AM  
Feb-27-20 03:09AM  
Feb-19-20 04:01PM  
Feb-12-20 04:01PM  
Feb-04-20 11:28AM  
Jan-31-20 04:41PM  
01:22PM  
Jan-17-20 05:40PM  
Dec-15-19 05:59AM  
Dec-09-19 09:52AM  
Dec-04-19 08:20PM  
Nov-25-19 03:00PM  
Nov-18-19 11:15AM  
Nov-15-19 12:54PM  
Nov-13-19 07:15PM  
Nov-12-19 04:01PM  
07:55AM  
07:20AM  
06:45AM  
Nov-11-19 05:15PM  
04:23PM  
04:02PM  
Nov-05-19 06:45AM  
Oct-30-19 10:33AM  
Oct-29-19 01:37PM  
Oct-20-19 08:08AM  
Oct-17-19 08:58AM  
Oct-16-19 07:06AM  
05:03AM  
Oct-15-19 05:13PM  
04:13PM  
01:13PM  
10:10AM  
07:50AM  
Oct-14-19 04:36PM  
04:01PM  
01:52PM  
Oct-11-19 10:00AM  
Oct-10-19 04:18PM  
07:31AM  
06:45AM  
Oct-01-19 07:22AM  
Sep-11-19 10:02AM  
Sep-06-19 09:40AM  
Sep-02-19 03:09PM  
Aug-29-19 07:38AM  
Aug-28-19 04:01PM  
Aug-12-19 01:47AM  
Aug-08-19 07:55AM  
06:40AM  
Aug-01-19 11:49AM  
06:45AM  
Jun-17-19 10:27AM  
Jun-11-19 04:36PM  
Jun-06-19 10:29AM  
07:37AM  
Jun-05-19 06:00PM  
Jun-04-19 07:00PM  
May-30-19 06:45AM  
May-23-19 01:47AM  
May-22-19 12:46PM  
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Soni Manmeet SinghCOO and CFOAug 14Buy100.213,000300,6303,000Aug 14 03:45 PM
Castellanos ElaineVP, Chief Accounting OfficerJun 01Sale143.972,000287,94015,146Jun 01 05:27 PM
Castellanos ElaineVP, Chief Accounting OfficerMar 02Sale194.322,000388,64015,146Mar 02 03:02 PM
Wilson Jason DouglasExecutive VP of OperationsDec 16Sale203.2610,0002,032,59112,950Dec 17 05:30 PM
Castellanos ElaineVP, Chief Accounting OfficerDec 02Sale194.242,000388,48015,146Dec 03 04:03 PM
ROSE WILLIAMMember of 10% owner groupNov 20Sale212.536,5911,400,77119,795Dec 05 05:22 PM
ROSE WILLIAMMember of 10% owner groupNov 19Sale210.002,000420,00026,386Dec 05 05:22 PM
Traweek James W JR10% OwnerNov 18Buy183.0040,2187,359,8943,063,567Nov 18 05:23 PM
McGaughy R Kent JrDirectorNov 18Buy183.0040,2187,359,8943,063,567Nov 18 05:21 PM
CPMG IncDirectorNov 18Buy183.0040,2187,359,894282,246Nov 18 05:20 PM
ROSE WILLIAMMember of 10% owner groupNov 18Sale202.041,000202,04028,386Dec 05 05:22 PM
Castellanos ElaineVP, Chief Accounting OfficerOct 28Sale200.004,000800,00015,146Oct 30 11:32 AM
Castellanos ElaineVP, Chief Accounting OfficerOct 25Sale190.002,000380,00015,146Oct 28 04:41 PM
Castellanos ElainePrincipal Accounting OfficerOct 18Sale170.002,000340,00011,933Oct 21 03:32 PM
Wilson Jason DouglasExecutive VP of OperationsOct 17Sale170.0010,0001,700,0007,350Oct 21 03:39 PM
Castellanos ElainePrincipal Accounting OfficerOct 15Sale147.5914,0002,066,24011,933Oct 17 04:51 PM
Wilson Jason DouglasExecutive VP of OperationsOct 15Sale146.1315,0002,191,9567,350Oct 15 04:03 PM
Wilson Jason DouglasExecutive VP of OperationsOct 14Sale100.0015,0001,500,0007,350Oct 15 04:03 PM
Castellanos ElainePrincipal Accounting OfficerOct 14Sale105.003,000315,00011,933Oct 15 03:52 PM